Viridian Therapeutics, Inc. $VRDN Shares Sold by Perceptive Advisors LLC

Perceptive Advisors LLC cut its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 61.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 1,170,829 shares of the company’s stock after selling 1,871,874 shares during the quarter. Perceptive Advisors LLC’s holdings in Viridian Therapeutics were worth $22,901,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after purchasing an additional 876 shares during the period. Goldman Sachs Group Inc. increased its stake in Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after purchasing an additional 310,998 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Viridian Therapeutics by 12.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares during the period. Envestnet Asset Management Inc. purchased a new stake in Viridian Therapeutics during the second quarter valued at about $187,000. Finally, Creative Planning purchased a new stake in Viridian Therapeutics during the second quarter valued at about $179,000.

Insider Activity

In other news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the transaction, the director owned 5,090,928 shares in the company, valued at approximately $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.40% of the company’s stock.

Viridian Therapeutics Stock Down 4.9%

Viridian Therapeutics stock opened at $18.92 on Friday. The firm has a market cap of $1.95 billion, a PE ratio of -5.70 and a beta of 0.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. The firm’s 50 day moving average price is $17.97 and its two-hundred day moving average price is $22.07. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. During the same quarter last year, the business posted ($0.87) EPS. The company’s revenue for the quarter was up 95.8% on a year-over-year basis. On average, research analysts predict that Viridian Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Analysts Set New Price Targets

VRDN has been the topic of several analyst reports. Wall Street Zen downgraded shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. The Goldman Sachs Group restated a “buy” rating and issued a $39.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a research note on Friday, May 15th. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Finally, Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a research note on Monday, June 29th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.79.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.